Skip to main content

Advertisement

Table 1 Fatty acid analysis of RWPE-1 cells that were supplemented with various fatty acids at the end of 48 hours of supplementation of various fatty acids

From: Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro

Fatty acids in RWPE-1 Composition percentage (%)
  Linolelaidic acid Linoleic acid γ-linolenic acid Arachidonic acid α-linolenic acid EPA DHA
Control 2.15 ± 0.50 0.38 ± 0.09 0.76 ± 0.13 0.92 ± 0.14 0.47 ± 0.09 0.86 ± 0.13 2.58 ± 0.49
LA(50 μM) 0.12 ± 0.05*** 1.59 ± 0.13** 0.49 ± 0.08* 1.76 ± 0.39** 0.19 ± 0.02* 1.73 ± 0.41* 2.60 ± 0.60
LA(150 μM) 0.18 ± 0.08*** 0.52 ± 0.18* 2.62 ± 0.64** 0.70 ± 0.12 0.33 ± 0.09 0.78 ± 0.14 0.69 ± 0.06**
GLA(25 μM) 1.64 ± 0.03* 0.19 ± 0.03* 1.44 ± 0.09* 21.95 ± 2.99*** 3.48 ± 0.57** N.D 0.43 ± 0.14**
GLA(50 μM) 1.13 ± 0.02** 0.65 ± 0.06* 1.01 ± 0.13* 27.21 ± 0.02*** 8.45 ± 0.19*** N.D 0.65 ± 0.01**
GLA(75 μM) N.D 0.99 ± 0.17* 12.34 ± 0.55*** 19.63 ± 1.47*** 10.59 ± 1.42*** N.D 0.88 ± 0.07**
AA(50 μM) 19.58 ± 0.83*** 7.3 ± 0.19** 4.57 ± 1.45** 7.01 ± 0.74** 0.69 ± 0.27* 5.52 ± 0.76*** 6.63 ± 0.17**
AA(100 μM) 21.22 ± 0.29*** 7.19 ± 0.18*** 4.04 ± 1.10** 10.28 ± 0.43*** 1.60 ± 0.22** 10.63 ± 1.27*** 9.30 ± 1.68**
ALA(50 μM) 0.56 ± 0.08*** 0.39 ± 0.07 0.97 ± 020 0.49 ± 0.05* 0.62 ± 0.13* 2.04 ± 0.41* 2.60 ± 0.64
ALA(150 μM) 0.17 ± 0.07*** 0.53 ± 0.08 0.77 ± 0.23 0.85 ± 0.13 0.86 ± 0.10* 1.92 ± 0.60** 0.43 ± 0.05**
EPA(50 μM) 0.92 ± 0.02** 4.67 ± 0.59*** 0.83 ± 0.02 N.D 2.61 ± 0.84** 1.14 ± 0.25 6.27 ± 0.34***
EPA(100 μM) 1.24 ± 0.32** 1.83 ± 0.34** 1.65 ± 0.34* 1.07 ± 0.04 0.53 ± 0.17 4.42 ± 0.43*** 7.22 ± 0.44***
DHA(50 μM) 1.14 ± 0.41** 1.41 ± 0.07** 0.93 ± 0.32 2.94 ± 0.59** N.D N.D 14.95 ± 0.63***
DHA 100 μM 1.54 ± 0.09* 1.38 ± 0.32** 2.41 ± 0.64** 2.29 ± 0.00** 0.44 ± 0.06 N.D 15.35 ± 0.08***
  1. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control.